55. Relapsing polychondritis Disease details / Clinical trials / Drug dev / DR info
Clinical trials : 8 / Drugs : 10 - (DrugBank : 9) / Drug target genes : 12 - Drug target pathways : 101
Drugs and their primary sponsors and trial info
Abatacept
Benaroya Research Institute
2011 Phase 1 NCT01272856 United States;
Ciclosporin
St. Marianna University School of Medicine
2010 - JPRN-UMIN000003869 Japan;
DIMENSION
St. Marianna University School of Medicine Division of Respiratory and Infectious Diseases, Department of Internal Medicine
2011 - JPRN-UMIN000006950 Japan;
Infliximab
Cambridge University Hospitals NHS Foundation Trust
2020 Phase 2 EUCTR2019-003964-30-GB United Kingdom;
Methotrexate
St. Marianna University School of Medicine
2010 - JPRN-UMIN000003869 Japan;
Rituximab
Cambridge University Hospitals NHS Foundation Trust
2020 Phase 2 EUCTR2019-003964-30-GB United Kingdom;
Tiotropium
St. Marianna University School of Medicine Division of Respiratory and Infectious Diseases, Department of Internal Medicine
2011 - JPRN-UMIN000006950 Japan;
Tocilizumab
Cambridge University Hospitals NHS Foundation Trust
2020 Phase 2 EUCTR2019-003964-30-GB United Kingdom;
Children's Hospital of Eastern Ontario
2010 - NCT01041248 Canada;
McMaster Children's Hospital
2010 Phase 2 NCT01104480 Canada;
Benaroya Research Institute
2011 Phase 1 NCT01272856 United States;
Ciclosporin
St. Marianna University School of Medicine
2010 - JPRN-UMIN000003869 Japan;
DIMENSION
St. Marianna University School of Medicine Division of Respiratory and Infectious Diseases, Department of Internal Medicine
2011 - JPRN-UMIN000006950 Japan;
Infliximab
Cambridge University Hospitals NHS Foundation Trust
2020 Phase 2 EUCTR2019-003964-30-GB United Kingdom;
Methotrexate
St. Marianna University School of Medicine
2010 - JPRN-UMIN000003869 Japan;
Rituximab
Cambridge University Hospitals NHS Foundation Trust
2020 Phase 2 EUCTR2019-003964-30-GB United Kingdom;
Tiotropium
St. Marianna University School of Medicine Division of Respiratory and Infectious Diseases, Department of Internal Medicine
2011 - JPRN-UMIN000006950 Japan;
Tocilizumab
Cambridge University Hospitals NHS Foundation Trust
2020 Phase 2 EUCTR2019-003964-30-GB United Kingdom;
Children's Hospital of Eastern Ontario
2010 - NCT01041248 Canada;
McMaster Children's Hospital
2010 Phase 2 NCT01104480 Canada;